Open AccessCompanion Biomarkers: Paving the Pathway to Personalized Treatment for Cancer
Author(s) -
Michael J. Duffy,
John Crown
Publication year - 2013
Publication title -
clinical chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.705
H-Index - 218
eISSN - 1530-8561
pISSN - 0009-9147
DOI - 10.1373/clinchem.2012.200477
Subject(s) - crizotinib , kras , epidermal growth factor receptor , cetuximab , medicine , anaplastic lymphoma kinase , erlotinib , lung cancer , gefitinib , cancer research , cancer , panitumumab , oncology , colorectal cancer , malignant pleural effusion
Companion biomarkers are biomarkers that are used in combination with specific therapies and that prospectively help predict likely response or severe toxicity. In this article we review the role of companion biomarkers in guiding treatment in patients with cancer.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom